← Leaderboards
Olivier Loudig
Albert Einstein College Of Medicine, Inc
$3,724,445
Attributed
$7,448,889
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2017–22$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$7,448,889 · 2
By mechanism
R01$6,400,457 · 1
R33$1,048,432 · 1
Top collaborators
- Thomas E Rohan6 shared
- Simon Daniel Spivack2 shared
Others in their field
Other Emerging Leaders on “Detection”
- Peter K Fritschel · California Institute Of Technology$78,820,000
- Mark Marino · Venturewell$48,913,644
- Julie Brisset · The University Of Central Florida Board Of Trustees$41,275,036
- Stuart Hellyar Hellyar$34,175,230
- Bryan Faller · Decatur Memorial Hospital$29,346,991
- Pamela Winer Goldberg · Medical Device Innovation Consortium$28,780,000
Research focus
DetectionNext Generation SequencingTissuesCase ControlMicrornasDiagnosisMolecularTechnologyEarly DiagnosisBaseSpecimenArchivesFormalinBiologyEthnic DiversityEpidemiology StudyFollow-UpGene ExpressionData ArchiveCommunitiesContralateralChemopreventionCancer InvasivenessClinical Management
Grant awards (8)
Exhaled small RNA biomarkers to detect and monitor airway disease$515,716
R33 · FY2022 · HL
Molecular markers of risk of subsequent invasive breast cancer in women wth ductal carcinoma in situ$1,134,871
R01 · FY2021 · CA
Exhaled small RNA biomarkers to detect and monitor airway disease$532,716
R33 · FY2021 · HL
Molecular markers of risk of subsequent invasive breast cancer in women wth ductal carcinoma in situ$1,225,240
R01 · FY2020 · CA
Molecular markers of risk of subsequent invasive breast cancer in women wth ductal carcinoma in situ$1,178,924
R01 · FY2019 · CA
Molecular markers of risk of subsequent invasive breast cancer in women wth ductal carcinoma in situ$1,106,638
R01 · FY2018 · CA
Molecular markers of risk of subsequent invasive breast cancer in women wth ductal carcinoma in situ$241,213
R01 · FY2018 · CA
Molecular markers of risk of subsequent invasive breast cancer in women wth ductal carcinoma in situ$1,513,571
R01 · FY2017 · CA